Catherine Van Kemseke
University of Liège
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Catherine Van Kemseke.
European Journal of Gastroenterology & Hepatology | 1997
Edouard Louis; Jacques Belaiche; Catherine Van Kemseke; Denis Franchimont; D. De Groote; Vincent Geenen; Jean-Yves Mary
Background/aims: Relapses of Crohns disease are difficult to predict. We assessed the value of serum level of interleukin‐6, tumour necrosis factor alpha (TNF‐&agr;) and soluble TNF receptors as predictors of relapse in quiescent Crohns disease. Patients/methods: Thirty‐six patients with inactive Crohns disease, treated or not, were included. Various clinical and biological parameters, including interleukin‐6, TNF‐&agr; and soluble TNF receptors serum levels were measured at inclusion in the study and the patients were followed clinically for 1 year. The relapse was defined as a Crohns Disease Activity Index (CDAI) greater than 150 with an increase greater than 100 compared to the inclusion value. We analysed the ability of these parameters to predict relapse in parallel to clinical characteristics and other laboratory parameters. Results: Among the 32 variables tested, interleukin‐6 serum level had the greatest ability to predict the time‐to‐relapse, with 17‐fold chance of relapse over a 1‐year period for patients with an interleukin‐6 serum level greater than 20 pg/ml than for patients with a lower level (P<0.001). A high serum level of the soluble TNF receptors p55 and p75 also had significant predictive value, in contrast to TNF‐&agr; serum levels. An interleukin‐6 serum level greater than 20 pg/ml and either an acid &agr;‐1glycoprotein level greater than 1.1 g/l or a soluble interleukin‐2 receptor serum level greater than 95 pM/l were risk factors selected by a stepwise multivariate analysis. In both models a good prognosis group was defined by the absence of the two risk factors, a bad prognostic group by the presence of the two risk factors and an intermediate in between. With both models, the good prognosis group included 17 patients who experienced no relapse over the 1‐year follow‐up, whereas all patients (seven with the first model and six with the second) in the bad prognosis group had a relapse during the follow‐up. Looking specifically at two homogeneous subgroups including either naturally/5‐aminosalicylic acid (5‐ASA) quiescent or corticoid quiescent patients, a very good predictive value for interleukin‐6 serum concentration was also found. Conclusion: Interleukin‐6 serum level alone or in association with other biological parameters such as acid &agr;‐1‐glycoprotein or the soluble interleukin‐2 receptor serum level may be useful for predicting the course of the disease in patients with quiescent Crohns disease.
Gut | 2013
Jose-Manuel Benitez; Marie-Alice Meuwis; Catherine Reenaers; Catherine Van Kemseke; Paul Meunier; Edouard Louis
Crohns disease is characterised by recurrent and/or chronic inflammation of the gastrointestinal tract leading to cumulative intestinal tissue damage. Treatment tailoring to try to prevent this tissue damage as well as achieve optimal benefit/risk ratio over the whole disease course is becoming an important aspect of Crohns disease management. For decades, clinical symptoms have been the main trigger for diagnostic procedures and treatment strategy adaptations. However, the correlation between symptoms and intestinal lesions is only weak. Furthermore, preliminary evidence suggests that a state of remission beyond the simple control of clinical symptoms, and including mucosal healing, may be associated with better disease outcome. Therefore monitoring the disease through the use of endoscopy and cross-sectional imaging is proposed. However, the degree of mucosal or bowel wall healing that needs to be reached to improve disease outcome has not been appropriately studied. Furthermore, owing to their invasive nature and cost, endoscopy and cross-sectional imaging are not optimal tools for the patients or the payers. The use of biomarkers as surrogate markers of intestinal and systemic inflammation might help. Two biomarkers have been most broadly assessed in Crohns disease: C-reactive protein and faecal calprotectin. These markers correlate significantly with endoscopic lesions, with the risk of relapse and with response to therapy. They could be used to help make decisions about diagnostic procedures and treatment. In particular, with the use of appropriate threshold values, they could determine the need for endoscopic or medical imaging procedures to confirm the disease activity state.
Best Practice & Research in Clinical Gastroenterology | 2011
Edouard Louis; Catherine Van Kemseke; Catherine Reenaers
Inflammatory bowel diseases (IBD) are classically divided in Crohns disease (CD) and ulcerative colitis (UC). However, these two entities are still heterogeneous and a further classification in subphenotypes is necessary. Clinical subphenotypes are easy to use, do not necessitate complicated tests and can already give very important information for the management of the patients. In CD, clinical subphenotypes are based on age at diagnosis, disease location and disease behaviour. Age at diagnosis allows to differentiating paediatric CD, classical young adult onset and more seldom CD of the elderly. These categories are associated with a different risk of development of complications and disabling disease and may have partly different pathophysiology. The classification on disease behaviour, including stricturin, penetrating or uncomplicated disease may have an impact on reponse to medical treatment and need for surgery. Finally the classification based on location is particularly relevant since it has been associated with different types of complications. Particularly ileal disease has been associated with the risk of surgery and colonic (particularly rectal) disease, with the risk of perianal disease. In UC, the classification in subphenotypes is essentially based on disease location, distinguishing proctitis, left-sided colitis and extensive colitis. This subclassification also has a very significant clinical relevance since extensive colitis has been associated with and increased risk of colon cancer, colectomy and even in some studies, mortality.
Digestive and Liver Disease | 2017
Caroline Bello; Arne Roseth; Jordi Guardiola; Catherine Reenaers; Alexandra Ruiz-Cerulla; Catherine Van Kemseke; Claudia Arajol; Christian Reinhard; Laurence Seidel; Edouard Louis
The aim of our work was to test the usability of fecal calprotectin (FC) home-based test in inflammatory bowel disease (IBD) patients. METHODS IBD patients were prospectively recruited. They had to measure FC with a dedicated tool and smartphone application, 5 times at two weeks intervals over an 8 weeks period. They had to fill in a usability questionnaire at the first and the last FC measurement. A System Usability Scale (SUS: 0-100) and the Global Score of Usability (GSU: 0-85) were calculated. FC was also centrally measured by ELISA. RESULTS Fifty-eight patients were recruited. Forty-two performed at least one FC measurement and 27 performed all the FC requested measurements. The median (IQR) SUS (0-100) at the first and last use were 85 (78-90) and 81 (70-88), respectively; the median (IQR) GSU (0-85) at the first and last use were 74 (69-80) and 77 (68-83), respectively. Adherence to the planned measurements and usability of the tool were higher in females and in less severe disease. The intra-class correlation coefficient between home-based and centrally measured FC was 0.88. CONCLUSION The adherence to home-based measurement of FC was fair. Usability scores for the home-based test were high. There was a good correlation with the centrally measured FC by ELISA.
International Archives of Allergy and Immunology | 1995
Edouard Louis; Denis Franchimont; Annouk Lamproye; Catherine Van Kemseke; Nicole Schaaf; Philippe Mahieu; Jacques Belaiche
The aim of our study was to determine the effect of a rectocolonic preimmunization with ovalbumin on the systemic immune response induced by a subsequent subcutaneous injection of this antigen in Balb/c mice. One rectocolonic, but not intragastric, administration of 25 mg of ovalbumin induced a detectable increase in serum anti-ovalbumin antibody level. The level reached was however much lower than after subcutaneous injection. Both intragastric and rectocolonic immunization with ovalbumin induced specific systemic cellular tolerance. However, after rectocolonic, but not intragastric, preimmunization there was no systemic humoral tolerance to this antigen. These differences in systemic immune responses after rectocolonic or intragastric administration of ovalbumin could be due to different stimulation of the systemic immune system or to differences between the colonic and small bowel mucosal immune system, which remain to be elucidated.
Archive | 2017
E Louis; Catherine Van Kemseke; Catherine Reenaers
An objective assessment of disease activity is an important prerequisite to clinical trials establishing the efficacy of new drugs or treatment strategies. Furthermore, while new objectives are developed for the global management of inflammatory bowel disease, leading to new treatment strategies aiming at a tighter control of the disease, it becomes important to have available user-friendly tools adequate for disease activity quantification and helping the clinician in treatment decisions. In ulcerative colitis, clinical activity of the disease has been rather well correlated to endoscopic activity and a large number of indices including or not an endoscopic assessment have been developed for a specific use in clinical trials. The simpler amongst them, like the Mayo score are also adapted for routine practice. In Crohn’s disease, the Crohn’s disease activity index has almost been the unique index used in clinical trials for more than 30 years. However, due to its poor correlation to intestinal lesions assessed either by endoscopy or cross-sectional imaging it is now abandoned in pivotal clinical trial, being replaced by a combination of endoscopic assessment and patients reported symptoms. For everyday routine practice, a simple score mainly based on patient’s symptoms, like the Harvey Bradshaw index or close variants potentially recorded by the patient him/herself, seems appropriate.
Archive | 2012
Edouard Louis; Catherine Van Kemseke; Catherine Reenaers
An objective assessment of disease activity is an important prerequisite to clinical trials establishing the efficacy of new drugs or treatment strategies. Furthermore, while new objectives are developed for the global management of inflammatory bowel disease, leading to new treatment strategies aiming at a tighter control of the disease, it becomes important to have available user-friendly tools adequate for disease activity quantification and helping the clinician in treatment decisions. In ulcerative colitis, clinical activity of the disease has been rather well correlated to endoscopic activity and a large number of indices including or not an endoscopic assessment have been developed for a specific use in clinical trials. However, experts are agreeing that an optimal index has still to be created and an international working group is currently tackling this task. In Crohn’s disease, the Crohn’s disease activity index has almost been the unique index used in clinical trials. The good correlation of a simplified score, the Harvey–Bradshaw index, with CDAI, has allowed its use in some recent long-term trials. Furthermore, this index which is easier to calculate may be more appropriate for routine practice. The correlation between endoscopic and clinical activity of the disease has been weak in Crohn’s disease. A Crohn’s disease endoscopic index of severity has first been developed and later a simplified endoscopic score for Crohn’s disease has been proposed aiming at simpler use. These scores have been used in recent controlled trials. For routine practice, their superiority over simple qualitative and descriptive assessment remains to be proven.
Alimentary Pharmacology & Therapeutics | 2012
Edouard Louis; Pierrette Gast; Catherine Van Kemseke; Catherine Reenaers
We thank de Hollander and Kuipers for their comments on our article, in which we demonstrated in a randomised clinical trial (RCT), that simvastatin as adjuvant therapy to the standard triple therapy improves the eradication rate of Helicobacter pylori infection. We agree with de Hollander and Kuipers in noting that the treatment groups were small and we did not provide clinical information, especially on gastrointestinal pathology. On the subject of whether H. pylori eradication treatment is more effective in patients with peptic ulcer disease (PUD) than in those with non-ulcer dyspepsia (NUD) or other non-ulcer gastric diseases this remains controversial. 4 Huang et al. in a systematic review including 22 studies showed that there is no convincing evidence to suggest that NUD patients respond to H. pylori eradication treatments differently from those with PUD. However, there was a trend for patients with PUD who received the classical triad of proton pump inhibitor, clarithromycin and amoxicillin for 7 days. Regarding the underlying mechanisms involved in H. pylori eradication, we proposed a number of speculative mechanisms. One of these speculative mechanisms is the anti-inflammatory effect of statins. We agree with de Hollander and Kuipers that statins, by exerting anti-inflammatory effects, may play a significant role in H. pylori eradication. In contrast, statins have not been proven to reduce the progression of gastritis to gastric cancer. More RCTs are needed to assess the efficacy of statins in H. pylori eradication focusing on the impact of 10–14 days treatment, and the role of long-term statin use in preventing or reducing the risk of progression to neoplasia in Barretts oesophagus and gastric cancer.
Transplantation | 2007
Arnaud De Roover; C. Coimbra; Olivier Detry; Catherine Van Kemseke; Jean-Paul Squifflet; Pierre Honore; Michel Meurisse
Endoscopy | 1999
Jacques Belaiche; Catherine Van Kemseke; Edouard Louis